Literature DB >> 6753895

Acute and long-term effects of captopril on exercise cardiac performance and exercise capacity in congestive heart failure.

B Kramer, N Topic, B Massie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6753895      PMCID： PMC1427515          DOI： 10.1111/j.1365-2125.1982.tb02071.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  27 in total

Review 1.  Renin-angiotensin system: biochemistry and mechanisms of action.

Authors:  M J Peach
Journal:  Physiol Rev       Date:  1977-04       Impact factor: 37.312

2.  Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilator prazosin.

Authors:  R R Miller; N A Awan; K S Maxwell; D T Mason
Journal:  N Engl J Med       Date:  1977-08-11       Impact factor: 91.245

3.  Hydralazine in the management of left ventricular failure.

Authors:  D H Fitchett; J A Neto; C M Oakley; J F Goodwin
Journal:  Am J Cardiol       Date:  1979-08       Impact factor: 2.778

4.  Hydrolysis of bradykinin and its higher homologues by angiotensin-converting enzyme.

Authors:  F Dorer; J W Ryan; J M Stewart
Journal:  Biochem J       Date:  1974-09       Impact factor: 3.857

5.  Hemodynamic effects of nitroglycerin ointment in congestive heart failure.

Authors:  W R Taylor; J S Forrester; P Magnusson; T Takano; K Chatterjee; H J Swan
Journal:  Am J Cardiol       Date:  1976-10       Impact factor: 2.778

6.  Treatment of chronic congestive heart failure with captopril, an oral inhibitor of angiotensin-converting enzyme.

Authors:  R Davis; H S Ribner; E Keung; E H Sonnenblick; T H LeJemtel
Journal:  N Engl J Med       Date:  1979-07-19       Impact factor: 91.245

7.  Oral hydralazine therapy for chronic refractory heart failure.

Authors:  K Chatterjee; W W Parmley; B Massie; B Greenberg; J Werner; S Klausner; A Norman
Journal:  Circulation       Date:  1976-12       Impact factor: 29.690

8.  Hemodynamic advantage of combined administration of hydralazine orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure.

Authors:  B Massie; K Chatterjee; J Werner; B Greenberg; R Hart; W W Parmley
Journal:  Am J Cardiol       Date:  1977-11       Impact factor: 2.778

9.  Hemodynamic improvement after oral hydralazine in left ventricular failure: a comparison with nitroprusside infusion in 16 patients.

Authors:  J A Franciosa; G Pierpont; J N Cohn
Journal:  Ann Intern Med       Date:  1977-04       Impact factor: 25.391

10.  Hemodynamic effects of trimazosin in patients with left ventricular failure.

Authors:  J A Franciosa; J N Cohn
Journal:  Clin Pharmacol Ther       Date:  1978-01       Impact factor: 6.875
View more
  5 in total

Review 1.  Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

Review 2.  Novel drugs and current therapeutic approaches in the treatment of heart failure.

Authors:  V V Bonarjee; K Dickstein
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

3.  Antihypertensive effect of single doses of enalapril in hypertensive patients treated with bendrofluazide.

Authors:  J Webster; D Newnham; O J Robb; J C Petrie
Journal:  Br J Clin Pharmacol       Date:  1987-02       Impact factor: 4.335

4.  The acute haemodynamic effects of intravenous enalaprilic acid (MK422) in patients with left ventricular dysfunction.

Authors:  R S Hornung; W S Hillis
Journal:  Br J Clin Pharmacol       Date:  1987-01       Impact factor: 4.335

5.  Current treatment of dilated cardiomyopathy.

Authors:  E K Massin
Journal:  Tex Heart Inst J       Date:  1991
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.